Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MarzAA · 1 trial · 6 indications
| Name | Type | Description |
|---|---|---|
| MarzAA (marzeptacog alfa [activated]) | BIOLOGICAL | Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant) |
MarzAA is an investigational monoclonal antibody being developed for the treatment of Hemophilia A. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MarzAA is being developed by Gyre Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol GYRE.
MarzAA is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for commercial use.
MarzAA has one completed Phase 1 clinical trial, identified as NCT04072237. This study enrolled 11 participants and evaluated the drug in adults with hemophilia, including those with inhibitors.
MarzAA is also known as Marzeptacog Alfa (Activated). The clinical trial NCT04072237 refers to the drug as Marzeptacog Alfa (Activated), indicating these names refer to the same investigational therapy.